KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Cost of Revenue (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed Cost of Revenue for 4 consecutive years, with -$3.8 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Cost of Revenue fell 173.04% year-over-year to -$3.8 million, compared with a TTM value of $1.6 million through Sep 2023, down 97.6%, and an annual FY2022 reading of $66.4 million, up 861.03% over the prior year.
  • Cost of Revenue was -$3.8 million for Q2 2023 at AbCellera Biologics, down from $3.8 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $44.6 million in Q1 2022 and bottomed at -$3.8 million in Q2 2023.
  • Average Cost of Revenue over 4 years is $6.8 million, with a median of $1.7 million recorded in 2021.
  • The sharpest move saw Cost of Revenue surged 4478.95% in 2021, then tumbled 173.04% in 2023.
  • Year by year, Cost of Revenue stood at $2.2 million in 2020, then decreased by 18.15% to $1.8 million in 2021, then fell by 12.37% to $1.6 million in 2022, then tumbled by 335.54% to -$3.8 million in 2023.
  • Business Quant data shows Cost of Revenue for ABCL at -$3.8 million in Q2 2023, $3.8 million in Q1 2023, and $1.6 million in Q4 2022.